Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis.

Conclusion: The class of PPIs is associated with a 1.75-fold increase in pancreatic cancer risk, confirmed in sensitivity analyses, but was independent of duration, and Defined Daily Dose.
PMID: 31928106 [PubMed - as supplied by publisher]

Source: Expert Opinion on Drug Safety - January 15, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research